RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Autolus Therapeutics Stock

Autolus Therapeutics Revenue 2024

Autolus Therapeutics Revenue

15.57 M USD

Ticker

AUTL

ISIN

US05280R1005

WKN

A2JNZJ

In 2024, Autolus Therapeutics's sales reached 15.57 M USD, a 816.67% difference from the 1.7 M USD sales recorded in the previous year.

The Autolus Therapeutics Revenue history

YEARREVENUE (undefined USD)GROSS MARGIN (%)
2029e592.09-
2028e490.69-
2027e332.79-
2026e155.76-
2025e73.85-
2024e15.57-
20231.7-
20226.36-
20212.33-
20201.72-
20192.91-
20181.41-
20171.69-
20161.21-
20151.21-

Autolus Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Autolus Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Autolus Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Autolus Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Autolus Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Autolus Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Autolus Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Autolus Therapeutics’s growth potential.

Autolus Therapeutics Revenue, EBIT and net profit per share

DateAutolus Therapeutics RevenueAutolus Therapeutics EBITAutolus Therapeutics Net Income
2029e592.09 M undefined0 undefined187.27 M undefined
2028e490.69 M undefined140.15 M undefined10.15 M undefined
2027e332.79 M undefined9.82 M undefined-85.3 M undefined
2026e155.76 M undefined-86.59 M undefined-137.24 M undefined
2025e73.85 M undefined-168.78 M undefined-184.2 M undefined
2024e15.57 M undefined-191.32 M undefined-222.86 M undefined
20231.7 M undefined-175.53 M undefined-208.38 M undefined
20226.36 M undefined-167.53 M undefined-148.84 M undefined
20212.33 M undefined-164.32 M undefined-142.1 M undefined
20201.72 M undefined-168.15 M undefined-142.09 M undefined
20192.91 M undefined-141.96 M undefined-123.85 M undefined
20181.41 M undefined-57.53 M undefined-44.75 M undefined
20171.69 M undefined-23.42 M undefined-19.73 M undefined
20161.21 M undefined-14.38 M undefined-12.55 M undefined
20151.21 M undefined-14.38 M undefined-12.55 M undefined

Autolus Therapeutics stock margins

The Autolus Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Autolus Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Autolus Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Autolus Therapeutics's sales revenue. A higher gross margin percentage indicates that the Autolus Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Autolus Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Autolus Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Autolus Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Autolus Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Autolus Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Autolus Therapeutics Margin History

Autolus Therapeutics Gross marginAutolus Therapeutics Profit marginAutolus Therapeutics EBIT marginAutolus Therapeutics Profit margin
2029e0 %0 %31.63 %
2028e0 %28.56 %2.07 %
2027e0 %2.95 %-25.63 %
2026e0 %-55.59 %-88.11 %
2025e0 %-228.54 %-249.42 %
2024e0 %-1,229.19 %-1,431.8 %
20230 %-10,337.34 %-12,272.26 %
20220 %-2,634.12 %-2,340.25 %
20210 %-7,052.36 %-6,098.71 %
20200 %-9,776.16 %-8,261.05 %
20190 %-4,878.35 %-4,256.01 %
20180 %-4,080.14 %-3,173.76 %
20170 %-1,385.8 %-1,167.46 %
20160 %-1,188.43 %-1,037.19 %
20150 %-1,188.43 %-1,037.19 %

Autolus Therapeutics Aktienanalyse

What does Autolus Therapeutics do?

Autolus Therapeutics PLC is a global biopharmaceutical company dedicated to the development of novel therapies for cancer. The company was founded in 2014 by an experienced team of scientists and executives from the biotech industry with the goal of revolutionizing cancer treatment. Autolus Therapeutics' business model is to develop and market novel cancer immunotherapies. The company utilizes innovative technologies such as CAR-T cell therapy and T-cell receptor (TCR) therapy. By targeting the immune system, cancer cells can be recognized and destroyed. Autolus Therapeutics operates a complex network of different sectors and areas to ensure comprehensive development and marketing of its products. This includes research and development, manufacturing and production, as well as clinical testing and approval of therapies. Currently, Autolus Therapeutics focuses on developing therapies for various types of cancer, such as leukemia, lymphoma, and solid tumors. The company has built a broad pipeline of products and therapeutic approaches that are currently in different phases of clinical development. The main focus is on an innovative CAR-T cell therapy, in which the body's own T cells are equipped with a chimeric antigen receptor (CAR) to specifically recognize and combat cancer cells. Autolus Therapeutics' different CAR-T therapies target specific antigens expressed on tumor cells. Another important part of Autolus Therapeutics' pipeline is T-cell receptor (TCR) therapies. T cells are equipped with specific receptors to also target and destroy cancer cells. These therapeutic approaches are currently in clinical development. Autolus Therapeutics collaborates closely with other companies and institutions in the industry to further advance the development and marketing of cancer therapies. This includes strategic partnerships with major pharmaceutical companies such as AstraZeneca and Bluebird Bio. The history of Autolus Therapeutics is characterized by rapid growth and high innovation. Shortly after its founding, the company was able to secure significant funding rounds and international partners. In the following years, the pipeline was further expanded, and the first clinical trials were initiated. Currently, Autolus Therapeutics employs over 250 people at locations in the United Kingdom and the United States. The company has a market capitalization of around $1.5 billion and is considered one of the most promising companies in the biopharmaceutical industry. In summary, Autolus Therapeutics is an innovative and ambitious company dedicated to the research and development of novel cancer therapies. The broad pipeline of products and therapeutic approaches, as well as the close partnerships in the industry, give hope for a promising future of the company. Autolus Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Autolus Therapeutics's Sales Figures

The sales figures of Autolus Therapeutics originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Autolus Therapeutics’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Autolus Therapeutics's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Autolus Therapeutics’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Autolus Therapeutics stock

How much revenue did Autolus Therapeutics generate this year?

Autolus Therapeutics has achieved a revenue of 15.57 M USD this year.

How much was the turnover of the company Autolus Therapeutics compared to the previous year?

The revenue of Autolus Therapeutics has increased by 816.67% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Autolus Therapeutics?

The revenue of Autolus Therapeutics is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Autolus Therapeutics measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Autolus Therapeutics so important for investors?

The revenue of Autolus Therapeutics is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Autolus Therapeutics pay?

Over the past 12 months, Autolus Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Autolus Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Autolus Therapeutics?

The current dividend yield of Autolus Therapeutics is .

When does Autolus Therapeutics pay dividends?

Autolus Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Autolus Therapeutics?

Autolus Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Autolus Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Autolus Therapeutics located?

Autolus Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Autolus Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Autolus Therapeutics from 9/29/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Autolus Therapeutics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Autolus Therapeutics in the year 2023?

In the year 2023, Autolus Therapeutics distributed 0 USD as dividends.

In which currency does Autolus Therapeutics pay out the dividend?

The dividends of Autolus Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Autolus Therapeutics

Our stock analysis for Autolus Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Autolus Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.